Estimating the burden of antimicrobial resistance: a systematic literature review

Abstract

BackgroundAccurate estimates of the burden of antimicrobial resistance (AMR) are needed to establish the magnitude of this global threat in terms of both health and cost, and to paramaterise cost-effectiveness evaluations of interventions aiming to tackle the problem. This review aimed to establish the alternative methodologies used in estimating AMR burden in order to appraise the current evidence base.MethodsMEDLINE, EMBASE, Scopus, EconLit, PubMed and grey literature were searched. English language studies evaluating the impact of AMR (from any microbe) on patient, payer/provider and economic burden published between January 2013 and December 2015 were included. Independent screening of title/abstracts followed by full texts was performed using pre-specified criteria. A study quality score (from zero to one) was derived using Newcastle-Ottawa and Philips checklists. Extracted study data were used to compare study method and resulting burden estimate, according to perspective. Monetary costs were converted into 2013 USD.ResultsOut of 5187 unique retrievals, 214 studies were included. One hundred eighty-seven studies estimated patient health, 75 studies estimated payer/provider and 11 studies estimated economic burden. 64% of included studies were single centre. The majority of studies estimating patient or provider/payer burden used regression techniques. 48% of studies estimating mortality burden found a significant impact from resistance, excess healthcare system costs ranged from non-significance to $1 billion per year, whilst economic burden ranged from $21,832 per case to over $3 trillion in GDP loss. Median quality scores (interquartile range) for patient, payer/provider and economic burden studies were 0.67 (0.56-0.67), 0.56 (0.46-0.67) and 0.53 (0.44-0.60) respectively.ConclusionsThis study highlights what methodological assumptions and biases can occur dependent on chosen outcome and perspective. Currently, there is considerable variability in burden estimates, which can lead in-turn to inaccurate intervention evaluations and poor policy/investment decisions. Future research should utilise the recommendations presented in this review.Trial registrationThis systematic review is registered with PROSPERO (PROSPERO CRD42016037510).Electronic supplementary materialThe online version of this article (10.1186/s13756-018-0336-y) contains supplementary material, which is available to authorized users.

Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing

“…Infection or colonization of patients with MDR bacteria often leave only very limited or even no treatment options, thus posing a potentially life-threatening risk to the individual patient in particular on intensive care units [2,3]. In addition, infection control measures to prevent spreading are required, resulting in increased efforts in patient care and costs for healthcare providers and the public healthcare systems [4,5]. Although action is needed on different national and international levels, understanding colonization, infection and transmission routes of these MDR resistant bacteria in the local hospital setting represent a crucial initial step towards implementation of harmonized, successful strategies to combat infections caused by MDR bacteria [1,4].…”

Antibacterial effects of low-temperature plasma generated by atmospheric-pressure plasma jet are mediated by reactive oxygen species

“…global scale. Finally, aside from the medical obstacles posed by treatment of patients with bacterial infections, the spread of antibiotic resistance also results in significant excess healthcare system costs and economic burdens with estimates of up to $1 billion per year and $3 trillion in worldwide gross domestic product losses respectively 5,6 .…”

Establishing BARA: Biological Nitrogen Fixation for Future Agriculture

“…Thus, antibiotic resistance in food system microbiomes has the potential to produce the same in HGMs. Currently, antibiotic resistance represents a major health challenge across the globe, adding $20 billion in excess cost alone to the US health system (Naylor et al, 2018). As microbes increase their resistance to the current antibiotics, humans are increasingly at risk of developing infections for which there is no effective treatment.…”